Interoception and Illness Perception Before and After Bariatric Surgery: See if interoceptive awareness changes with bariatric surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a monocentric, longitudinal observational study of adults with severe obesity undergoing bariatric evaluation. The researchers will collect psychological and clinical data before surgery and during follow-up to examine changes in interoceptive awareness and illness perception over time, and how these relate to psychological well-being and weight-related outcomes. The goal is to understand whether bariatric surgery and its physiological changes influence how patients perceive internal signals and illness, and whether these perceptions are linked to postoperative eating behaviors or weight trajectories. The study does not assign any intervention beyond standard clinical care, and data are analyzed to identify associations and temporal trends. This information may help inform pre- and post-surgical support for patients at risk of maladaptive eating or psychological distress.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 years or older.
* Diagnosis of severe or morbid obesity (body mass index ≥35 kg/m² with obesity-related comorbidities or ≥40 kg/m²).
* Undergoing multidisciplinary evaluation with indication for bariatric surgery.
* Ability to provide informed consent and complete self-administered questionnaires.

Exclusion Criteria:

* Age younger than 18 years.
* Presence of neurological disorders associated with cognitive impairment that may interfere with questionnaire completion.
* Pregnancy or breastfeeding at the time of enrollment.
* Inability to complete study assessments due to language barriers or other conditions limiting participation.

Where it's running

• Fondazione Policlinico Universitario A. Gemelli IRCCS
  Rome, Lazio, Italy Recruiting

Study contacts

• Principal investigator: Maria Rosaria Magurano — Fondazione Policlinico A. Gemelli IRCCS
• Study coordinator: Maria Rosaria Magurano, PC
• Email: mariarosaria.magurano@policlinicogemelli.it
• Phone: +393663940248

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.